Experimental Biology And Medicine | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Headlines Articles Press releases Experimental Biology And Medicine

Home
Companies
Experimental Biology And Medicine

BRIEF

published on 06/18/2024 at 15:05, 5 months 2 days ago

New Study Examines How Topical Naltrexone Restores Tear Production in Diabetic Dry Eye

Diabetic Dry Eye Naltrexone Tear Production OGF-OGFr Pathway Ocular Complications
BRIEF

published on 06/18/2024 at 15:05, 5 months 2 days ago

Une nouvelle étude examine comment la naltrexone topique rétablit la production de larmes dans la sécheresse oculaire diabétique

Naltrexone Sécheresse Oculaire Diabétique Production De Larmes Voie OGF-OGFr Complications Oculaires
PRESS RELEASE

published on 06/18/2024 at 15:00, 5 months 2 days ago

New Study Examines How Topical Naltrexone Restores Tear Production in Diabetic Dry Eye
Study led by Dr. Pat McLaughlin reveals topical naltrexone's effectiveness in reversing dry eye in diabetic rats. Findings point to OGF-OGFr pathway blockade as a promising treatment approach

Diabetes Experimental Biology And Medicine Naltrexone OGF-OGFr Pathway Dry Eye
BRIEF

published on 04/03/2024 at 15:05, 7 months 17 days ago

HTERT Vaccine Shows Promise in Therapy-Resistant Cancer Patients, Study Finds

Cancer Immunotherapy HTERT Vaccination Therapy-resistant Cancer Immune Response King's College London
BRIEF

published on 04/03/2024 at 15:05, 7 months 17 days ago

Le vaccin hTERT s’avère prometteur chez les patients atteints d’un cancer résistant au traitement, selon une étude

Immunothérapie Contre Le Cancer Vaccination HTERT Cancer Résistant Au Traitement Réponse Immunitaire King's College De Londres
PRESS RELEASE

published on 04/03/2024 at 15:00, 7 months 17 days ago

Study Shows hTERT Vaccination Induces Immunological Responses and Prevents Progression in a Subset of Therapy-Resistant Poor Prognosis Cancer Patients
A Phase 1 clinical trial led by James Spicer at King's College London showcases promising developments in immune therapy for solid tumours via hTERT vaccination. Published in Experimental Biology and Medicine

Solid Tumors Clinical Trial HTERT Vaccination Immune Therapy Experimental Biology And Medicine

Accesswire

Published on 11/21/2024 at 09:00, 1 hour 2 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 27 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 37 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 10 hours 2 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 11 hours 2 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 21 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 1 hour 1 minute ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 1 hour 2 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 1 hour 2 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 47 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 4 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 54 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 42 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE